BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

513 related articles for article (PubMed ID: 19491900)

  • 21. R1507, an anti-insulin-like growth factor-1 receptor (IGF-1R) antibody, and EWS/FLI-1 siRNA in Ewing's sarcoma: convergence at the IGF/IGFR/Akt axis.
    Huang HJ; Angelo LS; Rodon J; Sun M; Kuenkele KP; Parsons HA; Trent JC; Kurzrock R
    PLoS One; 2011; 6(10):e26060. PubMed ID: 22022506
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Proteasomal Degradation of the EWS-FLI1 Fusion Protein Is Regulated by a Single Lysine Residue.
    Gierisch ME; Pfistner F; Lopez-Garcia LA; Harder L; Schäfer BW; Niggli FK
    J Biol Chem; 2016 Dec; 291(52):26922-26933. PubMed ID: 27875302
    [TBL] [Abstract][Full Text] [Related]  

  • 23. EWS-FLI1, EWS-ERG, and EWS-ETV1 oncoproteins of Ewing tumor family all suppress transcription of transforming growth factor beta type II receptor gene.
    Im YH; Kim HT; Lee C; Poulin D; Welford S; Sorensen PH; Denny CT; Kim SJ
    Cancer Res; 2000 Mar; 60(6):1536-40. PubMed ID: 10749119
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PI3K/AKT signaling modulates transcriptional expression of EWS/FLI1 through specificity protein 1.
    Giorgi C; Boro A; Rechfeld F; Lopez-Garcia LA; Gierisch ME; Schäfer BW; Niggli FK
    Oncotarget; 2015 Oct; 6(30):28895-910. PubMed ID: 26336820
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The orphan nuclear receptor DAX1 is up-regulated by the EWS/FLI1 oncoprotein and is highly expressed in Ewing tumors.
    Mendiola M; Carrillo J; García E; Lalli E; Hernández T; de Alava E; Tirode F; Delattre O; García-Miguel P; López-Barea F; Pestaña A; Alonso J
    Int J Cancer; 2006 Mar; 118(6):1381-9. PubMed ID: 16206264
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ablation of EWS-FLI1 by USP9X inhibition suppresses cancer cell growth in Ewing sarcoma.
    Wang S; Huo X; Yang Y; Mo Y; Kollipara RK; Kittler R
    Cancer Lett; 2023 Jan; 552():215984. PubMed ID: 36330954
    [TBL] [Abstract][Full Text] [Related]  

  • 27. SLFN11 Is a Transcriptional Target of EWS-FLI1 and a Determinant of Drug Response in Ewing Sarcoma.
    Tang SW; Bilke S; Cao L; Murai J; Sousa FG; Yamade M; Rajapakse V; Varma S; Helman LJ; Khan J; Meltzer PS; Pommier Y
    Clin Cancer Res; 2015 Sep; 21(18):4184-93. PubMed ID: 25779942
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of Mithramycin Analogues with Improved Targeting of the EWS-FLI1 Transcription Factor.
    Osgood CL; Maloney N; Kidd CG; Kitchen-Goosen S; Segars L; Gebregiorgis M; Woldemichael GM; He M; Sankar S; Lessnick SL; Kang M; Smith M; Turner L; Madaj ZB; Winn ME; Núñez LE; González-Sabín J; Helman LJ; Morís F; Grohar PJ
    Clin Cancer Res; 2016 Aug; 22(16):4105-18. PubMed ID: 26979396
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Suppression of FOXO1 is responsible for a growth regulatory repressive transcriptional sub-signature of EWS-FLI1 in Ewing sarcoma.
    Niedan S; Kauer M; Aryee DN; Kofler R; Schwentner R; Meier A; Pötschger U; Kontny U; Kovar H
    Oncogene; 2014 Jul; 33(30):3927-38. PubMed ID: 23995784
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetic modeling optimizes inhibition of the 'undruggable' EWS-FLI1 transcription factor in Ewing Sarcoma.
    Hong SH; Youbi SE; Hong SP; Kallakury B; Monroe P; Erkizan HV; Barber-Rotenberg JS; Houghton P; Üren A; Toretsky JA
    Oncotarget; 2014 Jan; 5(2):338-50. PubMed ID: 24481407
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Junction region of EWS-FLI1 fusion protein has a dominant negative effect in Ewing's sarcoma in vitro.
    Jully B; Vijayalakshmi R; Gopal G; Sabitha K; Rajkumar T
    BMC Cancer; 2012 Nov; 12():513. PubMed ID: 23145994
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeted inhibition of histone deacetylase leads to suppression of Ewing sarcoma tumor growth through an unappreciated EWS-FLI1/HDAC3/HSP90 signaling axis.
    Ma Y; Baltezor M; Rajewski L; Crow J; Samuel G; Staggs VS; Chastain KM; Toretsky JA; Weir SJ; Godwin AK
    J Mol Med (Berl); 2019 Jul; 97(7):957-972. PubMed ID: 31025088
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of an inhibitor of the EWS-FLI1 oncogenic transcription factor by high-throughput screening.
    Grohar PJ; Woldemichael GM; Griffin LB; Mendoza A; Chen QR; Yeung C; Currier DG; Davis S; Khanna C; Khan J; McMahon JB; Helman LJ
    J Natl Cancer Inst; 2011 Jun; 103(12):962-78. PubMed ID: 21653923
    [TBL] [Abstract][Full Text] [Related]  

  • 34. EWS-FLI1 perturbs MRTFB/YAP-1/TEAD target gene regulation inhibiting cytoskeletal autoregulatory feedback in Ewing sarcoma.
    Katschnig AM; Kauer MO; Schwentner R; Tomazou EM; Mutz CN; Linder M; Sibilia M; Alonso J; Aryee DNT; Kovar H
    Oncogene; 2017 Oct; 36(43):5995-6005. PubMed ID: 28671673
    [TBL] [Abstract][Full Text] [Related]  

  • 35. GLI1 is a central mediator of EWS/FLI1 signaling in Ewing tumors.
    Joo J; Christensen L; Warner K; States L; Kang HG; Vo K; Lawlor ER; May WA
    PLoS One; 2009 Oct; 4(10):e7608. PubMed ID: 19859563
    [TBL] [Abstract][Full Text] [Related]  

  • 36. SPOP and OTUD7A Control EWS-FLI1 Protein Stability to Govern Ewing Sarcoma Growth.
    Su S; Chen J; Jiang Y; Wang Y; Vital T; Zhang J; Laggner C; Nguyen KT; Zhu Z; Prevatte AW; Barker NK; Herring LE; Davis IJ; Liu P
    Adv Sci (Weinh); 2021 Jul; 8(14):e2004846. PubMed ID: 34060252
    [TBL] [Abstract][Full Text] [Related]  

  • 37. EWS::FLI1 and HOXD13 Control Tumor Cell Plasticity in Ewing Sarcoma.
    Apfelbaum AA; Wu F; Hawkins AG; Magnuson B; Jiménez JA; Taylor SD; Wrenn ED; Waltner O; Pfaltzgraff ER; Song JY; Hall C; Wellik DM; Ljungman M; Furlan SN; Ryan RJH; Sarthy JF; Lawlor ER
    Clin Cancer Res; 2022 Oct; 28(20):4466-4478. PubMed ID: 35653119
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of the oncogenic fusion protein EWS-FLI1 causes G
    Zöllner SK; Selvanathan SP; Graham GT; Commins RMT; Hong SH; Moseley E; Parks S; Haladyna JN; Erkizan HV; Dirksen U; Hogarty MD; Üren A; Toretsky JA
    Sci Signal; 2017 Oct; 10(499):. PubMed ID: 28974650
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Selective usage of D-Type cyclins by Ewing's tumors and rhabdomyosarcomas.
    Zhang J; Hu S; Schofield DE; Sorensen PH; Triche TJ
    Cancer Res; 2004 Sep; 64(17):6026-34. PubMed ID: 15342383
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Loss of Stag2 cooperates with EWS-FLI1 to transform murine Mesenchymal stem cells.
    El Beaino M; Liu J; Wasylishen AR; Pourebrahim R; Migut A; Bessellieu BJ; Huang K; Lin PP
    BMC Cancer; 2020 Jan; 20(1):3. PubMed ID: 31898537
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.